151 related articles for article (PubMed ID: 2496196)
1. A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment.
Fornstedt B; Carlsson A
J Neural Transm; 1989; 76(2):155-61. PubMed ID: 2496196
[TBL] [Abstract][Full Text] [Related]
2. Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig.
Fornstedt B; Carlsson A
Neuropharmacology; 1991 May; 30(5):463-8. PubMed ID: 1907723
[TBL] [Abstract][Full Text] [Related]
3. In vivo autoxidation of dopamine in guinea pig striatum increases with age.
Fornstedt B; Pileblad E; Carlsson A
J Neurochem; 1990 Aug; 55(2):655-9. PubMed ID: 2370552
[TBL] [Abstract][Full Text] [Related]
4. Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea pig striatum.
Fornstedt B; Carlsson A
J Neurochem; 1991 Feb; 56(2):407-14. PubMed ID: 1988547
[TBL] [Abstract][Full Text] [Related]
5. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid.
Fornstedt B; Bergh I; Rosengren E; Carlsson A
J Neurochem; 1990 Feb; 54(2):578-86. PubMed ID: 2105377
[TBL] [Abstract][Full Text] [Related]
6. The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats.
Dluzen DE; Liu B
J Neural Transm Gen Sect; 1994; 95(3):209-22. PubMed ID: 7865176
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.
Fornstedt Wallin B
J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531
[TBL] [Abstract][Full Text] [Related]
8. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Loeffler DA; LeWitt PA; DeMaggio AJ; Juneau PL; Milbury PE; Matson WR
J Neural Transm Park Dis Dement Sect; 1995; 9(1):45-53. PubMed ID: 7605589
[TBL] [Abstract][Full Text] [Related]
9. Alteration in L-DOPA evoked dopamine and DOPAC output under conditions of impaired vesicular dopamine storage.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1998; 105(10-12):1091-101. PubMed ID: 9928880
[TBL] [Abstract][Full Text] [Related]
10. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
11. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
12. Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP.
Bagchi SP
Neurochem Res; 1998 Feb; 23(2):127-34. PubMed ID: 9475505
[TBL] [Abstract][Full Text] [Related]
13. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
14. A microdialysis study on striatal dopamine, 5-HT and metabolites in conscious rats after various treatments: evidence for extravesicular release of dopamine.
Wong PT; Teo WL; Lee T
Neuroreport; 1993 Oct; 5(1):53-6. PubMed ID: 7506588
[TBL] [Abstract][Full Text] [Related]
15. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.
Fornstedt B; Rosengren E; Carlsson A
Neuropharmacology; 1986 Apr; 25(4):451-4. PubMed ID: 3086766
[TBL] [Abstract][Full Text] [Related]
16. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
[TBL] [Abstract][Full Text] [Related]
17. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores.
Parker EM; Cubeddu LX
J Pharmacol Exp Ther; 1986 Apr; 237(1):179-92. PubMed ID: 3007736
[TBL] [Abstract][Full Text] [Related]
18. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
19. Effects of L-dopa and L-tyrosine on release of free and conjugated dopamine, homovanillic acid and dihydroxyphenylacetic acid from slices of rat striatum.
Tyce GM; Rorie DK
Life Sci; 1985 Dec; 37(25):2439-48. PubMed ID: 4079658
[TBL] [Abstract][Full Text] [Related]
20. Effects of reserpine and antidepressants on dopamine and DOPAC (3,4-dihydroxyphenylacetic acid) concentrations in the striatum, olfactory tubercle and median eminence of rats.
Fekete MI; Szentendrei T; Herman JP; Kanyicska B
Eur J Pharmacol; 1980 Jun; 64(4):231-8. PubMed ID: 7389821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
